AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|AAPL325.84+0.71 (+0.22%) ▲|ABBV259.84-0.15 (-0.06%) ▼|ABT111.32+2.39 (+2.19%) ▲|ACN187.12-0.97 (-0.52%) ▼|ADBE281.61-4.47 (-1.56%) ▼|AMAT438.54-3.31 (-0.75%) ▼|AMD456.87-2.74 (-0.60%) ▼|AMGN438.17+0.05 (+0.01%) ▲|AMT172.15-3.87 (-2.20%) ▼|AMZN254.77-0.15 (-0.06%) ▼|AVGO368.52-1.17 (-0.32%) ▼|AXP329.30+5.11 (+1.58%) ▲|BA209.56+3.90 (+1.90%) ▲|BAC62.38+0.39 (+0.62%) ▲|BKNG199.29+3.60 (+1.84%) ▲|BLK1,109.93-18.18 (-1.61%) ▼|BMY67.25+0.33 (+0.49%) ▲|BNY161.23+0.72 (+0.45%) ▲|BRK-B507.84+5.51 (+1.10%) ▲|C133.51+0.97 (+0.73%) ▲|CAT784.15+4.99 (+0.64%) ▲|CL90.72+1.09 (+1.22%) ▲|CMCSA27.13+0.83 (+3.14%) ▲|COF216.74+5.40 (+2.55%) ▲|COP136.78+0.59 (+0.43%) ▲|COST930.24-9.73 (-1.03%) ▼|CRM254.45-3.66 (-1.42%) ▼|CSCO108.89-0.86 (-0.78%) ▼|CVS98.11+0.51 (+0.52%) ▲|CVX211.96+0.91 (+0.43%) ▲|DE684.61+8.53 (+1.26%) ▲|DHR209.43+2.50 (+1.21%) ▲|DIS108.66+2.44 (+2.30%) ▲|DUK120.61+0.22 (+0.18%) ▲|EMR148.52+0.89 (+0.60%) ▲|FDX321.59-3.29 (-1.01%) ▼|GD364.09-5.33 (-1.44%) ▼|GE330.34-0.75 (-0.23%) ▼|GEV916.36+17.83 (+1.98%) ▲|GILD149.43-0.50 (-0.33%) ▼|GM84.73-0.91 (-1.06%) ▼|GOOG334.51+2.48 (+0.75%) ▲|GOOGL338.17+3.15 (+0.94%) ▲|GS999.83-2.73 (-0.27%) ▼|HD319.65-0.12 (-0.04%) ▼|HON206.60-3.38 (-1.61%) ▼|IBM232.47+1.07 (+0.46%) ▲|INTC90.12+1.15 (+1.29%) ▲|INTU342.80-2.13 (-0.62%) ▼|ISRG373.18+3.93 (+1.07%) ▲|JNJ274.76+3.57 (+1.32%) ▲|JPM354.69-0.26 (-0.07%) ▼|KO88.67+0.67 (+0.76%) ▲|LIN488.49+1.73 (+0.36%) ▲|LLY1,159.72-0.28 (-0.02%) ▼|LMT531.67-12.84 (-2.36%) ▼|LOW201.42+1.37 (+0.68%) ▲|LRCX287.81-2.39 (-0.82%) ▼|MA588.52+7.42 (+1.28%) ▲|MCD261.19+0.08 (+0.03%) ▲|MDLZ62.62+1.01 (+1.63%) ▲|MDT93.35+1.31 (+1.42%) ▲|META593.20+14.66 (+2.53%) ▲|MMM169.72-0.52 (-0.31%) ▼|MO69.77+0.20 (+0.29%) ▲|MRK150.66+0.80 (+0.53%) ▲|MS211.03-0.02 (-0.01%) ▼|MSFT496.11-4.91 (-0.98%) ▼|MU945.58+12.14 (+1.30%) ▲|NEE82.80-0.13 (-0.16%) ▼|NFLX82.17+1.36 (+1.68%) ▲|NKE38.39+0.27 (+0.71%) ▲|NOW137.32-5.58 (-3.90%) ▼|NVDA224.96+7.52 (+3.46%) ▲|ORCL144.73+3.41 (+2.41%) ▲|PEP141.13+1.34 (+0.96%) ▲|PFE28.87+0.32 (+1.12%) ▲|PG147.91+1.70 (+1.16%) ▲|PLTR168.02-11.90 (-6.61%) ▼|PM188.50+1.35 (+0.72%) ▲|QCOM169.10+2.49 (+1.49%) ▲|RTX200.99-4.18 (-2.04%) ▼|SBUX107.27+1.12 (+1.06%) ▲|SCHW108.55+0.27 (+0.24%) ▲|SO88.38+0.29 (+0.33%) ▲|SPG210.22-1.65 (-0.78%) ▼|T26.29+0.29 (+1.12%) ▲|TMO604.75+4.25 (+0.71%) ▲|TMUS187.17+5.01 (+2.75%) ▲|TSLA353.08-3.02 (-0.85%) ▼|TXN255.89+2.55 (+1.01%) ▲|UBER76.82+1.58 (+2.10%) ▲|UNH398.37+2.07 (+0.52%) ▲|UNP290.17-0.45 (-0.15%) ▼|UPS103.49+0.83 (+0.80%) ▲|USB62.34+1.13 (+1.84%) ▲|V377.93+5.26 (+1.41%) ▲|VZ50.63+0.33 (+0.65%) ▲|WFC88.89+1.85 (+2.13%) ▲|WMT106.15+0.23 (+0.22%) ▲|XOM163.26-1.29 (-0.78%) ▼|
21.3 C
New York
Wednesday, September 2, 2026

Tag: oncology

newssourceFORcompanyinformationcontent1releasesmarket

CAR/TCR/TIL Therapies in Oncology Research Service 2025 | An Essential Tool to Navigate the Fast-evolving Cancer Treatment Landscape

Revolutionize your oncology strategy with the CAR/TCR/TIL Therapies in Oncology Analytical Tool. Navigate the fast-evolving cancer treatment landscape, uncovering 236 new therapies and 5,021 events. Gain strategic insight on 2,374 drug programs, with real-time updates, KOL engagement, and innovative opportunities. 
Revolutionize your oncology strategy with the CAR/TCR/TIL Therapies in Oncology Analytical Tool. Navigate the fast-evolving cancer treatment landscape, uncovering 236 new therapies and 5,021 events. Gain strategic insight on 2,374 drug programs, with real-time updates, KOL engagement, and innovative opportunities.

Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 29, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company focused on the discovery and development...

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that it will release its financial...

Telix H1 2025 Results: Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025.

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

BlueSphere Bio CSO Alan Korman Recipient of Esteemed 2025 William B. Coley Award

Alan Korman honored in the category of tumor immunology for foundational role in checkpoint inhibitors PITTSBURGH, July 29, 2025 /PRNewswire/ -- BlueSphere Bio, a clinical...

Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report

ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion...

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9%

Milan, 29th July 2025 – The Board of Directors of Recordati S.p.A. approved the interim financial statements as of June 30, 2025, pursuant to Art. 154-ter of Italian Legislative Decree 58/1998 and subsequent amendments, prepared in accordance with said Decree and the CONSOB Issuers Regulation. The statements were prepared in accordance with International Accounting Standard (IAS) 34 requirements for interim reporting, based on the assessment, measurement and recognition criteria set by the IFRSs. The interim financial statements on June 30, 2025 – as well as the Independent Auditors’ report on such statements - will be available within the legal deadline at the company’s offices and on the company’s website (www.recordati.com) and can also be viewed on the authorized storage system 1Info(www.1Info.it).

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

The cell therapy market is anticipated to expand at a rapid pace owing to high incidence of chronic diseases, growing demand for novel treatments,...

Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases.

LIfT BioSciences announces grant of €12 million from Ireland’s Disruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOncology

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers